Skip to content

Improving Access to Psychiatric Care for Patients in Primary Care

Improving Access to Psychiatric Care and the Fluidity of Care Pathways for Patients Suffering From Mental Disorders in Primary Care in France: Evaluation of a Psychiatric Consultation-liaison System

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03508518
Acronym
DSPP-PSY
Enrollment
151
Registered
2018-04-25
Start date
2018-08-28
Completion date
2023-08-01
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mental Disorder

Keywords

Accessibility of health services, Access to psychiatric care, Consultation-liaison, General practitioner and psychiatrist collaboration, Care pathway

Brief summary

Getting a consultation with a psychiatrist within an appropriate time is one of the main issues reported by general practitioners (GP) for patients suffering from mental disorders in primary care. Consultation liaison in psychiatry is a system focused on general medicine-psychiatry collaboration. The aim of the present study is to evaluate the impact of the consultation-liaison on the adequacy of the access time to a psychiatric consultation according to the degree of urgency evaluated by the GP.

Detailed description

Faced with the saturation of the psychiatric care system, who recognizes the key role of the GP in mental health. Three-quarters of prescriptions for antidepressants and anxiolytics are performed by GPs, but less than one in four people with depression have been diagnosed and treated appropriately. The GPs describe difficulties in accessing psychiatric professionals and in particular to obtain a quick consultation with a psychiatrist. In different countries, psychiatric consultation-liaison (CL), centered on the collaboration of general medicine and psychiatry, have emerged. Two meta-analyzes and a Cochrane review were conducted on CL but no clinical trials were conducted in France. CL seems to improve patients' health at 3 months as well as their satisfaction and adherence to care. Results regarding the improvement of prescriptions from GP are encouraging. Better clinical trials are being requested and a need for medico-economic studies is also identified. In France, a psychiatry CL was born in Toulouse in 2017, the DSPP. The present study plans a 2 groups randomized clinical trial, one group of GPs having access to DSPP, the other not. For a period of 3 months, the GPs propose to any patient, for whom they want a psychiatric consultation, to participate in the study and address him/her to a psychiatrist. The DSPP is an evaluation center without long-term patient follow-up. Only patient referred by his/her GP can get into the DSPP.

Interventions

OTHERShared care device in psychiatry (DSPP)

The GPs of the intervention group will be able to refer their patients to the DSPP or to the routine care. The patient has a nursing telephone interview prior to one or few more psychiatric consultations. The time to obtain the psychiatric consultation is measured into the 2 groups. In both groups, questionnaires will be sent to the patient and their medico-administrative data will be collected passively over a period of 6 months after inclusion

OTHERUsual Care

psychiatric care available in the Haute Garonne: psychiatric consultation by a liberal psychiatrist or by a psychiatrist working in public health center.

Sponsors

Ministry of Health, France
CollaboratorOTHER_GOV
University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 15 years patient or older: * presenting mental suffering or a frequent or severe mental disorder * having consulted his GP who ask for psychiatric consultation * having given its consent for the use of its medico-administrative data * affiliated with the general health insurance scheme * of which the GP is from Haute Garonne and is voluntary to participate in the study * Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) and by one of the parents for minor participants

Exclusion criteria

* Patient with ongoing psychiatric follow-up * Patient unable to answer questionnaires (unable to read or write) * Patients receiving a measure of legal protection

Design outcomes

Primary

MeasureTime frameDescription
Number of patients who had access to a consultation with a psychiatrist2 to 21 working days after inclusionNumber of patients who had access to a consultation with a psychiatrist within 2 working days following the GP consultation for patients whose GP wishes an urgent consultation, within 7 working days for a quick consultation and within 21 working days for a non-urgent consultation.

Secondary

MeasureTime frameDescription
Number of passages to psychiatric emergencies6 monthsNumber of passages to psychiatric emergencies within 6 months M0 passively collected on the basis of the PMSI (Information Systems Medicalization Program) of psychiatric emergencies
Number of suicide attempts6 monthsNumber of suicide attempts and suicides within 6 months following M0 passively collected on the basis of the PMSI of the psychiatric emergencies and the Health Insurance
Mental health status by Symptom Checklist (SCL)date of inclusion, 1 month and 6 months after inclusionMental health status measured at M0, 1 month and 6 months by questionnaires hand-delivered by the GP at M0 and sent at 1 and 6 months : \- SCL-90-R scale: Scale exploring 9 symptomatic dimensions (somatization, obsession-compulsion, sensory traits, depression, anxiety, hostility, phobic anxiety, paranoid ideals, psychotic traits) by Likert scale in 5 points. Passing 15min.
Mental health status by Patient Health Questionnaire (PHQ)date of inclusion, 1 month and 6 months after inclusionMental health status measured at M0, 1 month and 6 months by questionnaires hand-delivered by the GP at M0 and sent at 1 and 6 months : \- the PHQ-9 scale for the diagnosis of major depressive episode and the intensity of depression. 9 questions are rated from 0 to 3 by the patient, ie a score of severity ranging from 0 to 27.
Duration of prescription of different drugsdate of inclusion, 1 month and 6 months after inclusionDuration of prescription of a benzodiazepine, antidepressant, hypnotic and antipsychotic treatment passively collected on the bases of Health Insurance
Evaluation of compliance with antidepressant prescriptionsdate of inclusion, 1 month and 6 months after inclusionComposite criterion for the evaluation of compliance with antidepressant prescriptions including drug type (first-line serotonin reuptake inhibitors (IRS): 0 or 1) and duration (6 months minimum: 0 or 1) with a total score of 0 to 2
Number of prescription treatment of mental disordersdate of inclusion, 1 month and 6 months after inclusionNumber of prescription of a benzodiazepine, antidepressant, hypnotic and antipsychotic treatment passively collected on the bases of Health Insurance
Number of days between M0 (GP consultation) and M1 (psychiatric consultation)6 monthsNumber of days between M0 (GP consultation) and M1 (psychiatric consultation) collected passively on the bases of Health Insurance, Information Systems Medicalization Program (PMSI) and DSPP
Patient satisfaction1 monthPatient satisfaction measured at 1 month of M0 by the Client Satisfaction Questionnaire (CSQ-8 scale)
Quality of life with EuroQol scale6 monthsQuality of life measured by the EuroQol (EQ-5D-5L) scale at M0 and 6 months by a clinical researcher by phone The EQ-5D-5L scale consists of 2 pages, a descriptive system EQ-5D and a visual analogue scale EQ . The descriptive system explores the following five dimensions: mobility, autonomy, usual activities, pain / discomfort and anxiety / depression. Each dimension is rated in 5 levels . The visual analogue scale is a vertical scale where the endpoints are labeled best health imaginable and worst health imaginable
GP satisfaction6 monthsGP satisfaction measured by questionnaire
Incremental Cost-Utility6 monthsto determine Incremental Cost-Utility collected passively on the bases of Health Insurance, PMSI and DSPP
Cost-Effectiveness Ratios of Patient Management Strategies6 monthsto determine Cost-Effectiveness Ratios of Patient Management Strategies collected passively by data on the bases of Health Insurance, PMSI and DSPP
Production costs6 monthsto determine production costs collected passively on the bases of Health Insurance, PMSI and DSPP
Employment status6 monthsOccupation, without profession (Number and duration of sick leave within 6 months following M0, passively collected on the bases of Health Insurance)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026